These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 34402157)

  • 21. Real-time CGM Is Superior to Flash Glucose Monitoring for Glucose Control in Type 1 Diabetes: The CORRIDA Randomized Controlled Trial.
    Hásková A; Radovnická L; Petruželková L; Parkin CG; Grunberger G; Horová E; Navrátilová V; Kádě O; Matoulek M; Prázný M; Šoupal J
    Diabetes Care; 2020 Nov; 43(11):2744-2750. PubMed ID: 32859607
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diabetes Knowledge and Metabolic Control in Type 1 Diabetes Starting With Continuous Glucose Monitoring: FUTURE-PEAK.
    Broos B; Charleer S; Bolsens N; Moyson C; Mathieu C; Gillard P; De Block C
    J Clin Endocrinol Metab; 2021 Jul; 106(8):e3037-e3048. PubMed ID: 33740049
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Flash glucose monitoring and automated bolus calculation in type 1 diabetes treated with multiple daily insulin injections: a 26 week randomised, controlled, multicentre trial.
    Secher AL; Pedersen-Bjergaard U; Svendsen OL; Gade-Rasmussen B; Almdal T; Raimond L; Vistisen D; Nørgaard K
    Diabetologia; 2021 Dec; 64(12):2713-2724. PubMed ID: 34495375
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the clinical effects of intermittently scanned and real-time continuous glucose monitoring in children and adolescents with type 1 diabetes: A retrospective cohort study.
    Urakami T; Terada H; Yoshida K; Kuwabara R; Mine Y; Aoki M; Shoji Y; Suzuki J; Morioka I
    J Diabetes Investig; 2022 Oct; 13(10):1745-1752. PubMed ID: 35532954
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A survey of physician experience and treatment satisfaction using fast-acting insulin aspart in people with type 1 or type 2 diabetes.
    Baru A; Amir S; Ekelund M; Montagnoli R; Da Rocha Fernandes JD
    Postgrad Med; 2020 May; 132(4):320-327. PubMed ID: 32306819
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Effect of Reduced Self-Monitored Blood Glucose Testing After Adoption of Continuous Glucose Monitoring on Hemoglobin A1c and Time in Range.
    Puhr S; Calhoun P; Welsh JB; Walker TC
    Diabetes Technol Ther; 2018 Aug; 20(8):557-560. PubMed ID: 30036082
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Associations of bolus insulin injection frequency and smart pen engagement with glycaemic control in people living with type 1 diabetes.
    Hellman J; Hartvig NV; Kaas A; Møller JB; Sørensen MR; Jendle J
    Diabetes Obes Metab; 2024 Jan; 26(1):301-310. PubMed ID: 37926903
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of intermittently scanned continuous glucose monitoring in adult type 1 diabetes patients with suboptimal glycaemic control: A multi-centre randomized controlled trial.
    Yan J; Zhou Y; Zheng X; Zheng M; Lu J; Luo S; Yang D; Deng H; Xu W; Bi Y; Bao W; Weng J
    Diabetes Metab Res Rev; 2023 May; 39(4):e3614. PubMed ID: 36670050
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion.
    Bode BW; Johnson JA; Hyveled L; Tamer SC; Demissie M
    Diabetes Technol Ther; 2017 Jan; 19(1):25-33. PubMed ID: 28055230
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Individualization of recommendations from the international consensus on continuous glucose monitoring-derived metrics in Japanese children and adolescents with type 1 diabetes.
    Urakami T; Yoshida K; Kuwabara R; Mine Y; Aoki M; Suzuki J; Morioka I
    Endocr J; 2020 Oct; 67(10):1055-1062. PubMed ID: 32565500
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of intermittently scanned continuous glucose monitoring on quality of life and glycaemic control in persons with type 1 diabetes: A 12-month follow-up study in real life.
    Duarte DB; Fonseca L; Santos T; Silva VB; Puga FM; Saraiva M; Silva IL; Teixeira S; Vilaverde J; Cardoso MH
    Diabetes Metab Syndr; 2022 Jun; 16(6):102509. PubMed ID: 35598543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison between preprandial vs. postprandial insulin aspart in patients with type 1 diabetes on insulin pump and real-time continuous glucose monitoring.
    Thuillier P; Sonnet E; Alavi Z; Roudaut N; Nowak E; Dion A; Kerlan V
    Diabetes Metab Res Rev; 2018 Sep; 34(6):e3019. PubMed ID: 29749032
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glycemic Outcomes in Adults With T1D Are Impacted More by Continuous Glucose Monitoring Than by Insulin Delivery Method: 3 Years of Follow-Up From the COMISAIR Study.
    Šoupal J; Petruželková L; Grunberger G; Hásková A; Flekač M; Matoulek M; Mikeš O; Pelcl T; Škrha J; Horová E; Škrha J; Parkin CG; Svačina Š; Prázný M
    Diabetes Care; 2020 Jan; 43(1):37-43. PubMed ID: 31530663
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Benefits of a Switch from Intermittently Scanned Continuous Glucose Monitoring (isCGM) to Real-Time (rt) CGM in Diabetes Type 1 Suboptimal Controlled Patients in Real-Life: A One-Year Prospective Study
    Préau Y; Galie S; Schaepelynck P; Armand M; Raccah D
    Sensors (Basel); 2021 Sep; 21(18):. PubMed ID: 34577338
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fast-acting insulin aspart (Fiasp®) improves glycemic outcomes when used with MiniMed
    Grosman B; Wu D; Parikh N; Roy A; Voskanyan G; Kurtz N; Sturis J; Cohen O; Ekelund M; Vigersky R
    Comput Methods Programs Biomed; 2021 Jun; 205():106087. PubMed ID: 33873075
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Application of medium-term metrics for assessing glucose homoeostasis: Usefulness, strengths and weaknesses.
    Monnier L; Colette C; Owens D
    Diabetes Metab; 2021 Mar; 47(2):101173. PubMed ID: 32561428
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glucose-lowering effects of 7-day treatment with SGLT2 inhibitor confirmed by intermittently scanned continuous glucose monitoring in outpatients with type 1 diabetes. A pilot study.
    Kurozumi A; Okada Y; Tanaka Y
    Endocr J; 2021 Mar; 68(3):361-369. PubMed ID: 33208570
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Continuous Glucose Monitoring Sensor Glucose Levels and Insulin Pump Infusion Set Wear-Time During Treatment with Fast-Acting Insulin Aspart: A Post Hoc Analysis of Onset 5.
    Gorst-Rasmussen A; Sturis J; Ekelund M
    Diabetes Technol Ther; 2022 Jan; 24(1):10-17. PubMed ID: 34524005
    [No Abstract]   [Full Text] [Related]  

  • 39. Glycemic control after switching to faster aspart in adults with type 1 diabetes.
    Fadini GP; Boscari F; Falaguasta D; Ferretto S; Maran A; Avogaro A; Bruttomesso D
    J Endocrinol Invest; 2022 Jun; 45(6):1181-1188. PubMed ID: 35103951
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fast-Acting Insulin Aspart and the Need for New Mealtime Insulin Analogues in Adults With Type 1 and Type 2 Diabetes: A Canadian Perspective.
    Senior P; Hramiak I
    Can J Diabetes; 2019 Oct; 43(7):515-523. PubMed ID: 30872107
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.